U.S. Viral Inactivation Market was valued at USD 0.27 billion in 2025 and is expected to reach around USD 0.83 billion by 2035 owing to the its highly advanced manufacturing processAustin, May 15, ...
Pharmaceutical Technology on MSN
Kyowa Kirin secures FDA approval for Crysvita dosing update
Following the update, healthcare providers can increase both the dose and frequency of Crysvita for XLH patients after treatment.
Zacks Small Cap Research on MSN
BBLG In Good Shape as Critical Tests Underway
By Brad Sorensen, CFA NASDAQ: BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine ...
Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month ...
Prices of generic semaglutide, the popular weight-loss and anti-diabetes drug, are expected to decline sharply in India over ...
Expanded dosing options support individualized treatment for adults with XLH PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., tod ...
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity ...
During Q1 FY2026, the Group paid a second interim dividend of 3.05 sen per share (payout in Q1 FY2025: 2.0 sen per share) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results